Read by QxMD icon Read

Hematology and Oncology

Margherita Condorelli, Isabelle Demeestere
Clinicians should provide fertility counseling to all patients receiving gonadotoxic treatment. International scientific societies have mainly focused on oncological patients, and fewer efforts have been made to apply these recommendations to women diagnosed with benign disease (eg benign hematological diseases, auto-immune diseases, and gynecological or genetic disorders). However, these indications account for 8% to 19% of the demand for fertility preservation. The risk of premature ovarian failure due to treatment, or to the disease itself, can be considered fairly high for many young women...
February 16, 2019: Acta Obstetricia et Gynecologica Scandinavica
Fenglin Cao, Xingang Li, Yiju Yang, Honghong Fang, Haixia Qu, Naibai Chang, Qingwei Ma, Weifan Cao, Jin Zhou, Wei Wang
The introduction of arsenic trioxide (ATO) in treatment of acute promyelocytic leukemia (APL) has resulted in high clinical complete remission (CR) rates over 90%. On the contrary, the risk for early death (ED) in APL patients treated with ATO continues to have a negative impact for optimization of APL therapeutics. There is an urgent need for precision medicine and biomarkers in clinical monitoring of ATO toxicity in APL, and ED in particular. This retrospective case series cohort proteomics study was conducted as a hypothesis generation effort and provides here several potential molecular leads on serum peptides expressed at different times after treatment with ATO in patients with APL...
February 2019: Omics: a Journal of Integrative Biology
Vincent J Lempers, Edmé Meuwese, Annelies M Mavinkurve-Groothuis, Stefanie Henriet, Inge M van der Sluis, Lidwien M Hanff, Adilia Warris, Birgit C P Koch, Roger J Brüggemann
Voriconazole is the mainstay of treatment for invasive aspergillosis in immunocompromised pediatric patients. Although Therapeutic Drug Monitoring (TDM) of voriconazole is recommended, it remains unknown if TDM-based dose adaptations result in target attainment. Patients <19 years from two pediatric hematologic-oncology wards were retrospectively identified based on unexplained high voriconazole trough concentrations (Cmin > 6 mg/l). Patient demographics, clinical characteristics, treatment, voriconazole dosing information, voriconazole Cmin before and after adjustment based on TDM were obtained...
February 13, 2019: Medical Mycology: Official Publication of the International Society for Human and Animal Mycology
Abdullah Ladha, Jianzhi Zhao, Elliot M Epner, Jeffrey J Pu
Mantle cell lymphoma is a relatively new recognized hematological malignant disease, comprising of 2.5-6% non-Hodgkin's lymphomas. The complexity of its clinical presentations (nodular pattern, diffuse pattern, and blastoid variant), variety in disease progression, and treatment response, make this disease a research focus to both experimental oncology and clinical oncology. Overexpression of cyclin D1 and chromosome t(11,14) translocation are the known molecular biomarkers of this disease. Mantle cell international prognostic index (MIPI), ki-67 proliferation index, and TP53 mutation are emerging as the prognostic biomarkers...
2019: Experimental Hematology & Oncology
Andrew Kirk, Jacob Pierce, Michelle Doll, Kimberly Lee, Amy Pakyz, Jihye Kim, Daniel Markley, Oveimar De la Cruz, Gonzalo Bearman, Michael P Stevens
The recently described proportion of carbapenem consumption metric was used to assess the effectiveness of formulary restriction for carbapenems for 2 units housing predominantly immunocompromised patients at a large academic medical center. Interrupted time series analysis revealed a significant decrease in meropenem use for hematology-oncology and bone marrow transplant units after restriction.
February 4, 2019: American Journal of Infection Control
M Kochanek, A Shimabukuro-Vornhagen, B Böll
The number of treatment options and success of treating patients with cancer have both significantly increased in recent years. However, many of these patients require intensive care due to comorbidities, treatment-associated complications, or severe infections. At the same time, the boundaries between what is feasible and sensible are difficult to draw. Over the past few years, awareness of the problems these cancer patients may have in the intensive care unit has increased and discussions have begun. This article intends to offer a discussion basis and also possible solution strategies...
February 6, 2019: Medizinische Klinik, Intensivmedizin und Notfallmedizin
Hematology Oncology Committee Of China Anti-Cancer Association, Leukemia And Lymphoma Group Society Of Hematology Chinese Medical Association
No abstract text is available yet for this article.
February 10, 2019: Zhonghua Yi Xue Yi Chuan Xue za Zhi, Zhonghua Yixue Yichuanxue Zazhi, Chinese Journal of Medical Genetics
Laura Finn, Sonia Malhotra
Palliative Care and its medical subspecialty, known as Palliative Medicine, is the care of anyone with a serious illness. This emerging field includes Hospice and comfort care, however, it is not limited to end-of-life care. Examples of the types of serious illness that Palliative Medicine clinicians care for include and are not limited to hematologic and oncologic diseases, such as cancer, advanced heart and lung diseases (e.g., congestive heart failure and chronic obstructive pulmonary disorder), advanced liver and kidney diseases, and advanced neurologic illnesses (e...
February 1, 2019: Healthcare (Basel, Switzerland)
Bruno C Medeiros, Bhavik J Pandya, Anna Hadfield, James Pike, Samuel Wilson, Cynthia Mueller, Cat N Bui, Scott C Flanders, Alex Rider, Laura E Horvath
OBJECTIVE: The aim of this analysis was to examine treatment patterns in patients with acute myeloid leukemia (AML) in routine clinical practice in the United States, including factors influencing the choice of front-line treatment intensity and the effect of age and treatment line. METHODS: We used data from the Adelphi AML Disease Specific Programme, a real-world, cross-sectional survey conducted in 2015. Physicians completed patient record forms providing patients' demographic and clinical characteristics...
February 2, 2019: Current Medical Research and Opinion
Charlotte Domblides, Lydia Lartigue, Benjamin Faustin
The metabolic reprogramming of tumor cells and immune escape are two major hallmarks of cancer cells. The metabolic changes that occur during tumorigenesis, enabling survival and proliferation, are described for both solid and hematological malignancies. Concurrently, tumor cells have deployed mechanisms to escape immune cell recognition and destruction. Additionally, therapeutic blocking of tumor-mediated immunosuppression has proven to have an unprecedented positive impact in clinical oncology. Increased evidence suggests that cancer metabolism not only plays a crucial role in cancer signaling for sustaining tumorigenesis and survival, but also has wider implications in the regulation of antitumor immune signaling through both the release of signaling molecules and the expression of immune membrane ligands...
January 31, 2019: Cells
Arzu Yazal Erdem, Fatma Demir Yenigürbüz, Esra Pekpak, Burcu Akıncı, Elif Aktekin, Cengiz Bayram, Zeynep Yıldız Yıldırmak, Eda Ataseven, Sinan Akbayram, İlgen Şaşmaz, Başak Taburoğlu Yılmaz, Ayşe Özkan, Sibel Akpınar Tekgündüz, Doğan Köse, Tuba Karapınar, Mustafa Büyükavcı, Ertan Sal, Turan Bayhan, Serap Kirkiz, Şule Ünal, Raziye Canan Vergin, Metin Çil, Barış Malbora, Ali Ayçiçek, Hüsniye Neşe Yaralı, Namık Yaşar Özbek
AIM: Since the beginning of the Syrian civil war, more than 3.5 million Syrians have been under temporary protection status in Turkey. Because beta-thalassemia (BT) is a prevalent disorder in the Mediterranean countries, we decided to estimate the prevalence of and make an overview of the demographic, socioeconomic, medical characteristics, and healthcare problems of refugee children with BT. PATIENTS: Eighteen Turkish Pediatric Hematology Oncology Centers (PHOC) with 318 refugee children from 235 families participated in the study...
February 1, 2019: Pediatric Blood & Cancer
Elizabeth A M Feijen, Wendy M Leisenring, Kayla L Stratton, Kirsten K Ness, Helena J H van der Pal, Elvira C van Dalen, Gregory T Armstrong, Gregory J Aune, Daniel M Green, Melissa M Hudson, Jacqueline Loonen, Kevin C Oeffinger, Leslie L Robison, Yutaka Yasui, Leontien C M Kremer, Eric J Chow
Importance: Anthracyclines are part of many effective pediatric cancer treatment protocols. Most pediatric oncology treatment groups assume that the hematologic toxicity of anthracycline agents is equivalent to their cardiotoxicity; for example, Children's Oncology Group substitution rules consider daunorubicin and epirubicin isoequivalent to doxorubicin, whereas mitoxantrone and idarubicin are considered 4 to 5 times as toxic as doxorubicin. Objective: To determine optimal dose equivalence ratios for late-onset cardiomyopathy between doxorubicin and other anthracyclines or the anthraquinone mitoxantrone...
January 31, 2019: JAMA Oncology
Georg Maschmeyer, Julien De Greef, Sibylle C Mellinghoff, Annamaria Nosari, Anne Thiebaut-Bertrand, Anne Bergeron, Tomas Franquet, Nicole M A Blijlevens, Johan A Maertens
A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists, infectious disease specialists, stem cell transplant experts, pulmonologists and radiologists have met within the framework of the European Conference on Infections in Leukemia (ECIL) to provide a critical state-of-the-art on infectious complications associated with immunotherapeutic and molecular targeted agents used in clinical routine. For brentuximab vedotin, blinatumomab, CTLA4- and PD-1/PD-L1-inhibitors as well as for ibrutinib, idelalisib, HDAC inhibitors, mTOR inhibitors, ruxolitinib, and venetoclax, a detailed review of data available until August 2018 has been conducted, and specific recommendations for prophylaxis, diagnostic and differential diagnostic procedures as well as for clinical management have been developed...
January 30, 2019: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Katrina Winsnes, Paul Sochacki, Carl Eriksson, Evan Shereck, Michael Recht, Kyle Johnson, Rebecca Loret De Mola, Linda Stork
BACKGROUND: Delirium affects 10% to 30% of patients in pediatric intensive care units (PICU) and is associated with increased length of stay and prolonged late sequela. There are no prospective trials evaluating delirium in the pediatric hematology, oncology, and bone marrow transplant (PHO) population. Hypothesizing that delirium is underrecognized in this population, our study aimed to identify the prevalence of delirium in hospitalized PHO patients and associated risk factors. PROCEDURE: PHO and PICU nurses were trained to use the Cornell Assessment for Pediatric Delirium and to record scores once every 12-hour shift...
January 29, 2019: Pediatric Blood & Cancer
Jaroslav Racek, Daniel Rajdl, Alexandra Jungová
No abstract text is available yet for this article.
February 2019: Clinical Chemistry
Leehu Zysberg, Sharon Hai, Najib Dally
This study tests a new comprehensive model accounting for the role of demographic, personal, and social factors in quality of life (QOL) among a sample of hematological cancer patients. We hypothesized that positive and negative affect would mediate the associations between these factors and QOL. Seventy-two patients were recruited at an outpatient hematological clinic in a midsized medical center in northern Israel. They completed measures of QOL, social support, positive and negative affect, and emotional intelligence (EI)...
January 28, 2019: Journal of Clinical Psychology in Medical Settings
Sultan Aydin Köker, Bengü Demirağ, Neryal Tahta, Nuri Bayram, Yeşim Oymak, Tuba H Karapinar, Salih Gözmen, Mine Düzgöl, Hazer Erçan Bozyer, Canan Vergin, İlker Devrim
BACKGROUND: Acute viral respiratory infections are common causes of febrile episodes in children. There are still limited data about distribution of acute viral respiratory infections in children with cancer. OBJECTIVE: The first aim of this study was to evaluate the viral etiology and seasonality of acute viral respiratory infection in pediatric patients with cancer in a 3-year study. Our second aim was to evaluate the impact of viral infections on delaying the patients' chemotherapy or radiotherapy...
January 25, 2019: Journal of Pediatric Hematology/oncology
C Chabannon, R Bouabdallah, S Fürst, A Granata, C Saillard, N Vey, D Mokart, E Fougereau, C Lemarie, B Mfarrej, D Blaise, B Calmels
CAR-T cells are genetically modified human lymphocytes and gene therapy medicinal products. They are developed to treat cancers that express a membrane antigen targeted by the CAR. The FDA approved the two first-in-class medicinal products in 2017 and EMA in August 2018; both are autologous CAR-T cells targeting CD19 that is expressed at the surface of normal B-cells throughout their differentiation, and on B-cell lymphoid malignancies. Clinical efficacy was demonstrated for B-cell acute lymphoblastic leukemias, non-Hodgkin's lymphoma and chronic lymphocytic leukemia, although the marketing authorizations are less liberal in terms of indications...
January 24, 2019: La Revue de Médecine Interne
Martin Schmidt-Hieber, Daniel Teschner, Georg Maschmeyer, Enrico Schalk
Infections are among the most frequent complications in patients with hematological and oncological diseases. They might be classified as fever of unknown origin, and microbiologically or clinically documented infections. Optimal duration of antimicrobial treatment is still unclear in these patients. Areas covered: We provide an overview on the management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation. Expert opinion: Patients with febrile high-risk neutropenia should be treated empirically with an anti-pseudomonal agent such as piperacillin/tazobactam...
January 28, 2019: Expert Review of Anti-infective Therapy
Abbey Elsbernd, Maiken Hjerming, Camilla Visler, Lisa Lyngsie Hjalgrim, Carsten Utoft Niemann, Kirsten Arntz Boisen, Jens Jakobsen, Helle Pappot
BACKGROUND: Adolescent and young adult (AYA) oncology and hematology is a developing field of medicine, focusing on a population that faces many challenges throughout medical treatment and beyond. Mobile health (mHealth) interventions provide exciting new opportunities for improvement of health-related quality of life (HRQoL) in AYAs with cancer. Many smartphone apps are currently available for AYAs with cancer; however, for AYAs with cancer, very few apps have been designed with direct input from AYAs themselves or have demonstrated their effectiveness and benefit...
November 1, 2018: JMIR formative research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"